Biocom's program serves to extend effective, well-established and easy-to-perform self-collection nasal swab testing to over 1,300 members across the state under the Food and Drug Administration 's Emergency Use Authorization framework.
Test purchases come equipped with Everlywell Lens, a comprehensive reporting dashboard for human resource representatives, which gives organizations visibility into the status of individual kits, from registration to results.
The program with Everlywell will provide Biocom members access to rt-PCR tests that will determine the presence or absence of RNA from the SARS-CoV-2-virus.
Met with the highest standards of quality, safety, and reliability, Everlywell's straightforward sample collection, free shipping, and physician-reviewed results and insights ensure that we are connecting our members with one of the best testing solutions in the market.
The laboratories used by Everlywell are CLIA-certified and many are CAP-accredited, which means they must meet or exceed high precision, accuracy, and validity standards, obtain both state and federal certifications, and submit themselves to regular inspections as well as independent third-party performance verifications.
Biocom works on behalf of over 1,300 members to drive public policy, build an enviable network of industry leaders, create access to capital, introduce cutting-edge workforce development and STEM education programs, and create robust value-driven purchasing programs.
Biocom a public voice for research institutions and life science companies that fuel the California economy.
Biocom Purchasing Group offers member-driven strategic sourcing solutions. Biocom members save on average 15-25x their membership dues through the Biocom Purchasing Group.
In 2019, members collectively saved USD 280m and brought more ideas to market through a broad range of products, services and technologies offered by endorsed Purchasing Group suppliers.
Everlywell connects individuals to certified labs offering a suite of validated lab tests including Cholesterol, Heart Health, Fertility, STIs, Lyme Disease, Testosterone, Thyroid and more, including one of the only FDA-authorized at-home sample collection test kits for COVID-19 and the first at-home sample collection test kits for fertility, high-risk HPV, and indoor and outdoor allergies.
Prices start at USD 49 and tests are generally covered by Flexible Spending and Health Savings Accounts.
The Austin-based company was founded in 2015 and is advised by a Scientific advisory board that includes some of the nation's top scientists from Harvard, MIT, Google and NYU. Everlywell was selected as one of Fast company's Most Innovative Companies in 2019.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA